ZURICH (Reuters) – Lonza will commission a dedicated suite at its Houston site for clinical and commercial supply of U.S.-based Altimmune’s COVID-19 vaccine candidate, the Swiss contract drug manufacturer said on Friday.
Altimmune is developing a COVID-19 vaccine candidate that is administered via nasal spray, and has begun Phase 1 safety studies in humans, with expected data to come in the second quarter.
(Reporting by John Miller)
